Gilead Sciences: Leukemia, Myeloid, Acute trials
The registry lists 10 Leukemia, Myeloid, Acute studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 7Phase 2 1Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaTerminatedNCT05079230Phase 3Results posted
- Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04789408Phase 1Results posted
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedNCT04778397Phase 3Results posted
- Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
- Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
- US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNo longer availableNCT05627466
- Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
- CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesCompletedNCT02678338Phase 1
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1